Canagliflozin - CAS# 842133-18-0 Compound 1 Acebutolol HCl is a cardioselective

Acebutolol HCl is a cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors

inhibits growth hormone

suggestive of secondary transcriptional effects and transcription of BRD4 and BRD3 are unaffected

3 mg/kg/dose with Acyclovir (10 mg/kg/dose) are protective when compared to the vehicle treated group against HSV-2

Canagliflozin - CAS# 842133-18-0 Compound 1 Acebutolol HCl is a cardioselectiveCanagliflozin (INN, trade name Invokana) is a drug for the treatment of type 2 diabetes. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson. Canagliflozin is an inhibitor of subtype 2 sodium glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the